Thymosin Beta-4 Dosing: 750mcg Loading Protocol

Thymosin Beta-4 (TB-4) is a naturally occurring 43-amino-acid peptide involved in tissue repair, angiogenesis, and cell migration. It's the most abundant actin-sequestering molecule in mammalian cells and the parent molecule of the TB-500 fragment.

No FDA-approved human dosing exists. Everything below is extrapolated from animal research and community experience. This is not medical advice.

Quick Reference: Community Protocol

Loading phase: 500 mcg to 1 mg daily for 2 weeks to achieve tissue saturation. Maintenance: 500 mcg twice weekly for 2-6 additional weeks. For the full TB-4 profile, vendor pricing, and comparison with TB-500, see our Thymosin Beta-4 peptide page.

Cycling Details

TB-4 uses a two-phase approach: loading then maintenance. The loading phase (2 weeks daily) saturates tissue levels during the acute healing window. TB-4's short plasma half-life (~2 hours) means frequent dosing is needed for consistent tissue-level concentrations.

The maintenance phase (2x weekly) sustains support while reducing peptide consumption. This mirrors tissue repair timelines seen in animal studies — rapid cell migration and angiogenesis in weeks 1-2, followed by ECM remodeling in weeks 3-8 (Malinda et al., 1999).

Typical protocol lengths: Tendon/ligament/muscle injuries: 4-6 weeks. Skin and wound healing: 4-8 weeks. Post-surgical recovery: 6-8 weeks. Chronic inflammatory conditions: 8-12 weeks with cycling.

Routes of Administration

Subcutaneous (most common): For localized injuries, inject within a few inches of the injury site. For systemic healing, abdomen or anywhere with subcutaneous fat. Use 29-31 gauge insulin syringe.

Intramuscular: Used when targeting a specific muscle injury — direct injection into the muscle belly. Less common than subcutaneous.

Peri-lesional: Direct injection around wound sites, used in dermal wound research.

Reconstitution Quick Reference

10 mg vial + 2 mL BAC water = 5 mg/mL. Your 750 mcg dose is 15 units; 1 mg is 20 units on an insulin syringe.

Swirl gently — do not shake. Refrigerate at 2-8°C and use within 28 days.

Where These Numbers Come From

Community TB-4 doses are conservatively extrapolated from a large body of animal research, with some reference to human safety data.

Animal Study Doses: Nearly all TB-4 research uses 6 mcg/mouse IP (~0.24 mg/kg). Using standard allometric scaling to a 70 kg human gives a human equivalent of ~17 mg single dose, or ~5-10 mg/week. Community doses (5-10 mg/week loading, 2-5 mg/week maintenance) sit in the conservative middle of this range.

Phase I Human Safety (Ruff et al., 2010): Massive IV doses of 42, 140, 420, and 1,260 mg were well-tolerated in healthy subjects — no dose-limiting toxicity. This was safety testing, not therapeutic dosing.

Key mechanisms: Actin sequestration for cell migration (Mannherz & Huff, 2011), VEGF-driven angiogenesis (Philp et al., 2003), NF-kB suppression for anti-inflammatory effects (Sosne et al., 2007), and Akt survival signaling (Bock-Marquette et al., 2004).

Stacking Protocols

TB-4 + BPC-157 (Popular Healing Stack)

TB-4 + GHK-Cu

TB-4 vs TB-500

For the complete comparison, see TB-4 vs TB-500.

Side Effects & Safety

• Injection site irritation — mild, transient
• Rare mild fatigue — occasional community report
• No hormonal disruption — unlike some peptides
• Phase I human safety — IV doses up to 1,260 mg well-tolerated with no serious adverse events
• No mutagenic or carcinogenic effects in long-term animal studies
• Theoretical angiogenic concern — pro-angiogenic effects raise questions about existing tumors, though no evidence of tumor promotion exists
• No long-term human data at community doses

Frequently Asked Questions

What is the standard TB-4 dose for healing?

500 mcg to 1 mg daily during loading (weeks 1-2), then 500 mcg twice weekly for maintenance (weeks 3-8). Extrapolated from animal studies using allometric scaling.

How long should I cycle TB-4?

4-8 weeks total. Loading (2 weeks daily) then maintenance (2-6 weeks, 2x/week). Acute injuries run shorter; chronic conditions may extend to 8-12 weeks.

Should I inject TB-4 near the injury?

For specific injuries, injecting nearby is common — animal studies showed benefits with local injection. For systemic healing, anywhere subcutaneously works. TB-4 distributes systemically regardless of site.

What's the difference between TB-4 and TB-500 dosing?

TB-4 uses higher weekly doses (5-10 mg loading) because it's the full 43-amino acid peptide with multiple active domains. TB-500 is the fragment — lower doses (3.5 mg/week) are standard.

How do I reconstitute TB-4?

Add 2 mL BAC water to a 10 mg vial (5 mg/mL). 750 mcg = 15 units; 1 mg = 20 units on an insulin syringe. Swirl gently, refrigerate, use within 28 days.

Related Guides

• Thymosin Beta-4 Peptide Page — Vendor pricing, stack protocols, and full profile
• Thymosin Beta-4 Benefits — Full breakdown of healing and regenerative effects
• TB-4 vs TB-500 — Full peptide vs synthetic fragment comparison
• TB-500 Dosing Guide — The fragment of TB-4
• BPC-157 Dosing Guide — Top stacking partner for healing
• BPC-157 vs TB-500 — Head-to-head comparison
• Calculate Your Thymosin Beta-4 Cycle Cost — Estimate vials needed and total cost

References

For educational and research purposes only. This is not medical advice. TB-4 is not FDA-approved for any indication.